 |
| 12-Dec-12 | Reiterated |
Wedbush |
Outperform |
$93 → $110 |
|
| 24-Aug-12 | Initiated |
Stifel Nicolaus |
Hold |
|
|
| 02-Aug-12 | Downgrade |
Needham |
Buy → Hold |
|
|
| 17-May-12 | Reiterated |
Rodman & Renshaw |
Mkt Outperform |
$22 → $40 |
|
| 17-May-12 | Reiterated |
Needham |
Buy |
$23 → $32 |
|
| 21-Feb-12 | Upgrade |
RBC Capital Mkts |
Sector Perform → Outperform |
$15 → $34 |
|
| 09-Dec-11 | Downgrade |
RBC Capital Mkts |
Outperform → Sector Perform |
$15 → $15 |
|
| 09-Dec-11 | Downgrade |
Global Hunter Securities |
Buy → Neutral |
$15 → $15 |
|
| 07-Dec-11 | Initiated |
Rodman & Renshaw |
Mkt Outperform |
$20 |
|
| 11-Nov-11 | Resumed |
Needham |
Buy |
$14 |
|
| 20-Jun-11 | Reiterated |
RBC Capital Mkts |
Outperform |
$10 → $15 |
|
| 07-Jun-10 | Reiterated |
Wedbush |
Outperform |
$8 → $16 |
|
| 14-Apr-10 | Reiterated |
Roth Capital |
Buy |
$7 → $11 |
|
| 12-Mar-10 | Initiated |
Roth Capital |
Buy |
$7 |
|
| 12-Feb-10 | Downgrade |
BWS Financial |
Buy → Hold |
|
|
| 29-Jan-10 | Initiated |
Merriman |
Buy |
|
|
| 17-Feb-09 | Reiterated |
RBC Capital Mkts |
Outperform |
$4 → $2 |
|
| 13-Oct-08 | Upgrade |
BWS Financial |
Hold → Buy |
$2 |
|
| 03-Sep-08 | Upgrade |
RBC Capital Mkts |
Sector Perform → Outperform |
|
|
| 17-Aug-07 | Upgrade |
BWS Financial |
Sell → Hold |
$2 |
|
|
|
| 23-May-13 01:03PM | 5 Stocks Raising The Drugs Industry Higher at TheStreet |
| 09:31AM | PHARMACYCLICS INC Files SEC form 8-K, Amendment or Waiver to Code of Ethics EDGAR Online |
| 22-May-13 03:50PM | FDA Designation for Synageva Candidate Zacks |
| 21-May-13 07:00AM | 2013 FDA Drug Approval Calendar at TheStreet |
| 03:45AM | PHARMACYCLICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online |
| 19-May-13 06:30PM | Tackling Cancer: Leukemia's Biggest Current and Upcoming Players at Motley Fool |
| 16-May-13 01:23PM | Wall Street Transcript Interview with Finny Kuruvilla, Portfolio Manager of the Eventide Gilead Fund: Investing in Health Care Innovation Wall Street Transcript |
| 15-May-13 11:02PM | PHARMACYCLICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online |
| 07:09PM | With 'Cell Death' Drugs, Bristol-Myers May Win No Matter What at Forbes |
| 06:00PM | ASCO '13 Preview: Roche's Next-Gen Rituxan Steps Up at TheStreet |
| 06:00PM | ASCO '13 Preview: Gilead's Big Cancer Debut at TheStreet |
| 12:24PM | Three Value-Presenting Stocks With Upgrades on Monday at Motley Fool |
| 14-May-13 11:02PM | PHARMACYCLICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Submission of Matters to a Vote of EDGAR Online |
| 13-May-13 03:53PM | Pharmacyclics Rises On Unusually High Volume (PCYC) at TheStreet +8.82% |
| 03:06PM | 3 Biotech Stocks Spiking With Big Volume at TheStreet |
| 10-May-13 02:57PM | 6 Superstars For Your Biotech Portfolio: John McCamant at Seeking Alpha +6.07% |
| 11:44AM | Climbing the Wall of Worry at Motley Fool |
| 07-May-13 01:58PM | Right Time To Buy This Pharmaceutical Company? at Motley Fool |
| 10:14AM | PHARMACYCLICS INC Files SEC form 10-Q, Quarterly Report EDGAR Online |
| 04-May-13 04:43PM | 2 Winners and 3 Losers from This Weeks Earnings Storm at Wall St. Cheat Sheet |
| 03-May-13 10:18PM | Biotech Watchlist 2013 Update: Exciting Ideas Have Explosive Potential at Seeking Alpha |
| 02-May-13 01:30PM | Wider-Than-Expected Loss at Pharmacyclics Zacks |
| 11:08AM | David Amsellem, Managing Director and Senior Research Analyst at Piper Jaffray & Co., Interviews with The Wall Street Transcript: Alternative Dosage Forms Create Barriers Against Competition in Generics Wall Street Transcript |
| 01-May-13 09:40PM | Pharmacyclics Management Discusses Q1 2013 Results - Earnings Call Transcript at Seeking Alpha -6.44% |
| 07:37PM | Pharmacyclics Earnings: Everything You Must Know Now at Wall St. Cheat Sheet |
| 06:37PM | Pharmacyclics posts bigger 1Q loss on stock costs AP |
| 06:20PM | Can This Biotech Soar Again? at Motley Fool |
| 04:05PM | Pharmacyclics Reports First Quarter 2013 Results PR Newswire |
| 09:17AM | PHARMACYCLICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibit EDGAR Online |
| 07:07AM | Q3 2013 Pharmacyclics Earnings Release - After Market Close CCBN |
| 28-Apr-13 01:54PM | Tracking Cash Inflows: A Good Method to Locate Investment Opportunities at Motley Fool |
| 26-Apr-13 11:48AM | Ramin Najafi, Founder, Chairman and CEO of NovaBay Pharmaceuticals, Inc. (NBY), Interviews with The Wall Street Transcript Wall Street Transcript |
| 25-Apr-13 04:30PM | FDA Designation for Merck Candidate Zacks |
| 24-Apr-13 04:05PM | Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call PR Newswire |
| 23-Apr-13 05:30PM | Abbott - Epizyme Collaborate Zacks |
| 04:41PM | Pharmacyclics Larger Than S&P 500 Component Interpublic Group of Companies at Forbes |
| 01:54PM | Are These Billion-Dollar Biotechs Overvalued? at Motley Fool |
| 19-Apr-13 02:00PM | PCYC Completes RESONATE Enrollment Zacks |
| 18-Apr-13 11:02PM | PHARMACYCLICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online |
| 04:15PM | Pharmacyclics completes enrollment of phase 3 study for leukemia treatment theflyonthewall.com |
| 04:10PM | InPlay: Pharmacyclics completes enrollment of First Phase III ibrutinib CLL study - RESONATE and announces completion of enrollment of Phase II ibrutinib MCL study - SPARK Briefing.com |
| 04:08PM | Mega-Hedge Fund Focusing on the Life Sciences at Motley Fool |
| 04:05PM | Pharmacyclics Completes Enrollment of First Phase III Ibrutinib CLL Study - RESONATE and Announces Completion of Enrollment of Phase II Ibrutinib MCL Study - SPARK PR Newswire |
| 17-Apr-13 02:20PM | Tackling Cancer: Non-Hodgkin Lymphoma's Biggest Current & Upcoming Players at Motley Fool |
| 16-Apr-13 08:37PM | These Cutting-Edge Science Stocks Are Soaring at Motley Fool |
| 15-Apr-13 04:00PM | Health Care's Biggest Movers and Shakers at Motley Fool |
| 11:54AM | Pharmacyclics Earns 4th Milestone Zacks |
| 11-Apr-13 02:19PM | Quest Diagnostics shares climb on glowing words from Goldman at MarketWatch |
| 12:26PM | Quest Diagnostics shares climb on glowing words from Goldman at MarketWatch |
| 09:54AM | A "Breakthrough" May Be on the Way for Breast Cancer Patients at Motley Fool |
| 09:31AM | PHARMACYCLICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online |
| 06:31AM | InPlay: Pharmacyclics triggers fourth milestone payment for enrollment of 5th patient in frontline Phase III CLL study Briefing.com |
| 06:30AM | Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study PR Newswire |
| 10-Apr-13 09:44AM | FDA's Breakthrough Therapy Designation More Bling Than Bite at Motley Fool |
| 09-Apr-13 05:01PM | Pharmacyclics Incorporated (PCYC): Drugs' Featured Daily Laggard at TheStreet |
| 08-Apr-13 01:00PM | InPlay: Pharmacyclics reports Phase II ibrutinib monotherapy study shows CLL patients achieved rapid and sustainable disease control irrespective of age or high risk prognostic factor Briefing.com |
| 01:00PM | Phase II Ibrutinib Monotherapy Study Shows CLL Patients Achieved Rapid and Sustainable Disease Control Irrespective of Age or High Risk Prognostic Factor PR Newswire |
| 10:27AM | PHARMACYCLICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online |
| 10:15AM | Analysts: Yum Brands Get a Bird Flu Warning and 2 New Opinions Investors Must Read Now at Wall St. Cheat Sheet |
| 08:50AM | InPlay: Pharmacyclics trading up 5% following third breakthrough therapy designation for Ibrutinib from the FDA (see 6:30) Briefing.com |
| 06:35AM | Pharmacyclics says FDA grants Breakthrough Therapy Designation for ibrutinib theflyonthewall.com |
| 06:30AM | InPlay: Pharmacyclics announces third breakthrough therapy designation for Ibrutinib from the FDA Briefing.com |
| 06:30AM | Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration PR Newswire |
| 06-Apr-13 12:15PM | Health Policy Is in Flux, and So Are 2 Health Funds at New York Times |
| 05-Apr-13 11:37PM | The Wild Story Behind A Promising Experimental Cancer Drug at Forbes |
| 05:29PM | The 9 Levels Of Healthcare / Biotechnology And Who Should Invest - Part 1 at Seeking Alpha |
| 05:00AM | Pharmacyclics Incorporated Stock Downgraded (PCYC) at TheStreet |
| 26-Mar-13 03:54PM | 4 Healthcare Stock Stories for Tuesday Investment Wellness at Wall St. Cheat Sheet |
| 25-Mar-13 10:03AM | Analysts: Pharmacyclics Presents Buying Chance and 3 New Opinions Investors Must Know Now at Wall St. Cheat Sheet |
| 23-Mar-13 08:30AM | 3 Horrendous Health-Care Stocks This Week at Motley Fool |
| 22-Mar-13 06:04PM | Nasdaq stocks posting largest percentage decreases AP |
| 01:17PM | Nasdaq stocks posting largest percentage decreases AP |
| 21-Mar-13 06:05PM | Nasdaq stocks posting largest percentage decreases AP -8.43% |
| 20-Mar-13 05:37PM | Under-the-Radar Hedge Fund Focusing on Pharma at Motley Fool |
| 09:14AM | New Stock Coverage: Has Whole Foods Become Spoiled? at Minyanville |
| 19-Mar-13 05:01PM | Pharmacyclics Incorporated (PCYC): Today's Featured Drugs Laggard at TheStreet |
| 01:04PM | INCY, PCYC, EW And A, 4 Health Care Stocks Pushing The Sector Lower at TheStreet |
| 18-Mar-13 12:02PM | Which Medical Device Companies Have the Most Upside Potential in 2013? An Expert Equity Analyst Discusses Renal Denervation and Transcatheter Heart Valves, as well as the European Slowdown Wall Street Transcript |
| 14-Mar-13 04:19PM | PHARMACYCLICS INC Files SEC form 8-K, Other Events EDGAR Online |
| 11-Mar-13 03:28PM | Pharmacyclics to Sell Shares Zacks |
| 01:19PM | Snatch PCYC Even Cheaper Than Its Secondary? at Forbes |
| 08-Mar-13 05:25PM | PHARMACYCLICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statements EDGAR Online |
| 05:01PM | Pharmacyclics Incorporated (PCYC): Today's Featured Health Care Laggard at TheStreet |
| 05:00PM | Finding the Next Home Run Stock at Motley Fool |
| 12:45PM | Nasdaq clues suggest more upward valuation at MarketWatch |
| 08:19AM | InPlay: Pharmacyclics prices public offering of common stock at $94.20 Briefing.com |
| 08:00AM | Pharmacyclics, Inc. Prices Public Offering of Common Stock PR Newswire |
| 07-Mar-13 04:39PM | InPlay: Pharmacyclics has commenced an underwritten registered public offering of 2,200,000 shares of its common stock Briefing.com |
| 04:37PM | Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock PR Newswire |
| 11:14AM | For stocks, the game remains the same at MarketWatch |
| 11:14AM | For stocks, the game remains the same at MarketWatch |
| 06-Mar-13 01:26PM | Infinity Pharmas stock up on buy rating at bizjournals.com |
| 01:04PM | PHARMACYCLICS INC Financials EDGAR Online Financials |
| 12:05PM | 5 Stocks Pushing The Health Care Sector Higher at TheStreet |
| 05-Mar-13 01:04PM | PHARMACYCLICS INC Financials EDGAR Online Financials |
| 10:04AM | Pharmacyclics Stock Hits New 52-Week High (PCYC) at TheStreet |
| 01-Mar-13 10:56AM | This Is One Incredible CEO at Motley Fool |
| 26-Feb-13 06:39PM | Tackling Cancer: The Current and Upcoming Players at Motley Fool |
| 04:29PM | PHARMACYCLICS INC Files SEC form 10-K, Annual Report EDGAR Online |
| 12:57PM | The return of the European bogeyman at MarketWatch |
|
|
| Pharmacyclics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of small-molecule drugs for the treatment of cancer and immune mediated diseases. Its principal products candidates in clinical development include ibrutinib, which is under multiple Phase III studies in hematologic malignancies; a BTK inhibitor lead optimization program targeting anti-inflammatory and autoimmune indications; PCI-27483, an inhibitor of Factor VIIa that is in phase II clinical trial for the treatment of pancreatic cancer; and a HDAC inhibitor abexinostat, which is in Phase I and II clinical trials for the treatment of solid tumors and hematological malignancies. The company's clinical development and product candidates are small-molecule enzyme inhibitors designed to target key biochemical pathways involved in human diseases with critical unmet needs. It has a collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize ibrutinib and other structurally related compounds; collaboration and license agreement with Les Laboratoires Servier to develop and commercialize abexinostat; and license agreement with Novo Nordisk A/S to research and develop PCI-27483. Pharmacyclics, Inc. was founded in 1991 and is headquartered in Sunnyvale, California. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Buggy Joseph J | VP, Research | Feb 11 | Option Exercise | 0.86 | 12,000 | 10,320 | 18,701 | Feb 11 07:19 PM | | Buggy Joseph J | VP, Research | Feb 11 | Sale | 69.97 | 12,000 | 839,666 | 6,701 | Feb 11 07:19 PM | | Loury David J | Chief Scientific Officer | Feb 05 | Option Exercise | 2.76 | 20,000 | 55,200 | 20,325 | Feb 05 07:08 PM | | Loury David J | Chief Scientific Officer | Feb 05 | Sale | 70.58 | 20,000 | 1,411,510 | 325 | Feb 05 07:08 PM | | McGreivy Jesse | VP, Clinical Science | Jan 17 | Sale | 67.29 | 583 | 39,229 | 0 | Jan 18 06:37 PM | | Hemmi Gregory | VP Chemical Operations | Jan 11 | Option Exercise | 3.69 | 5,000 | 18,471 | 27,992 | Jan 11 07:30 PM | | Hemmi Gregory | VP Chemical Operations | Jan 11 | Sale | 67.11 | 5,000 | 335,550 | 22,992 | Jan 11 07:30 PM | | Loury David J | Chief Scientific Officer | Jan 09 | Sale | 66.30 | 10,531 | 698,205 | 325 | Jan 10 03:15 PM | | Loury David J | Chief Scientific Officer | Jan 08 | Option Exercise | 4.16 | 10,000 | 41,600 | 10,325 | Jan 08 07:15 PM | | Loury David J | Chief Scientific Officer | Jan 08 | Sale | 64.70 | 10,000 | 647,000 | 325 | Jan 08 07:15 PM | | Fardis Maria | EVP, Operations and Alliances | Jan 08 | Sale | 65.00 | 2,500 | 162,500 | 976 | Jan 09 07:05 PM | | Fardis Maria | EVP, Operations and Alliances | Jan 07 | Option Exercise | 6.84 | 3,500 | 23,940 | 6,976 | Jan 07 08:23 PM | | Fardis Maria | EVP, Operations and Alliances | Jan 07 | Sale | 64.20 | 3,500 | 224,700 | 3,476 | Jan 07 08:23 PM | | van den Broek Richard | Director | Dec 31 | Sale | 58.50 | 7,171 | 419,476 | 108,445 | Jan 02 02:20 PM | | van den Broek Richard | Director | Dec 28 | Sale | 57.98 | 18,354 | 1,064,125 | 108,445 | Dec 28 04:38 PM | | Hemmi Gregory | VP Chemical Operations | Dec 27 | Option Exercise | 6.04 | 12,900 | 77,883 | 35,892 | Dec 27 06:22 PM | | van den Broek Richard | Director | Dec 27 | Sale | 58.02 | 11,931 | 692,239 | 126,799 | Dec 28 04:38 PM | | Hemmi Gregory | VP Chemical Operations | Dec 27 | Sale | 59.20 | 12,900 | 763,725 | 22,992 | Dec 27 06:22 PM | | Hemmi Gregory | VP Chemical Operations | Dec 26 | Option Exercise | 4.47 | 100 | 447 | 23,092 | Dec 27 06:22 PM | | Hemmi Gregory | VP Chemical Operations | Dec 26 | Sale | 59.00 | 100 | 5,900 | 22,992 | Dec 27 06:22 PM | | Loury David J | Chief Scientific Officer | Dec 20 | Option Exercise | 4.16 | 39,469 | 164,191 | 39,794 | Dec 21 07:09 PM | | Loury David J | Chief Scientific Officer | Dec 20 | Sale | 61.12 | 39,469 | 2,412,274 | 325 | Dec 21 07:09 PM | | Erdtmann Rainer M | VP, IR Education Training | Dec 18 | Option Exercise | 0.91 | 59,558 | 54,198 | 87,043 | Dec 18 07:05 PM | | Erdtmann Rainer M | VP, IR Education Training | Dec 18 | Sale | 62.48 | 59,558 | 3,721,092 | 27,485 | Dec 18 07:05 PM | | Erdtmann Rainer M | VP, IR Education Training | Dec 17 | Option Exercise | 0.91 | 34,442 | 31,342 | 61,927 | Dec 18 07:05 PM | | Buggy Joseph J | VP, Research | Dec 17 | Option Exercise | 0.75 | 50,000 | 37,500 | 56,701 | Dec 17 07:10 PM | | Buggy Joseph J | VP, Research | Dec 17 | Sale | 62.14 | 50,000 | 3,106,840 | 6,701 | Dec 17 07:10 PM | | Erdtmann Rainer M | VP, IR Education Training | Dec 17 | Sale | 62.73 | 34,442 | 2,160,698 | 27,485 | Dec 18 07:05 PM |
|
|
|
|
|
|
